I am a board-certified medical oncologist who specializes in the use of novel immunotherapies to treat melanoma and other cancers. I work closely with a multidisciplinary team of medical oncologists, surgeons, radiation oncologists, and research nurses in the Immunotherapeutics Clinical Core (a specialized center for Phase 1 studies of new immunotherapy agents) and on the Melanoma and Sarcoma Service.
My research is focused on the development of new ways to use the immune system to treat cancer. As a laboratory member in the Ludwig Center at Memorial Sloan Kettering, I have been involved in developing innovative approaches to monitoring patients treated with immunotherapy. Our hope is to better understand how immunotherapy can be used to help patients with cancer and to expand this promising treatment modality into new areas.
- Clinical Expertise: Melanoma; Immunotherapy
- Languages Spoken: English
- Education: MD, PhD, University of Connecticut School of Medicine
- Residencies: University of California, San Francisco, Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Margaret K. Callahan
- A Phase I Study of BMS-986016 Alone and with Nivolumab in Patients with Advanced Solid Tumors
- A Phase I Study of Varlilumab plus Nivolumab in Patients with Advanced Solid Tumors
- A Phase I/II Study of Nivolumab Alone and with Ipilimumab in Patients with Advanced or Metastatic Solid Tumors
- A Phase II Study Assessing Mediators of Response to Nivolumab and Ipilimumab in Patients with Advanced Melanoma or Bladder Cancer